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Abstract
Introduction: We previously reported an association between tumor-specific 3-hydroxy-3-methylglutharyl-
coenzyme A reductase (HMG-CoAR) expression and a good prognosis in breast cancer. Here, the predictive value
of HMG-CoAR expression in relation to tamoxifen response was examined.
Methods: HMG-CoAR protein and RNA expression was analyzed in a cell line model of tamoxifen resistance using
western blotting and PCR. HMG-CoAR mRNA expression was examined in 155 tamoxifen-treated breast tumors
obtained from a previously published gene expression study (Cohort I). HMG-CoAR protein expression was
examined in 422 stage II premenopausal breast cancer patients, who had previously participated in a randomized
control trial comparing 2 years of tamoxifen with no systemic adjuvant treatment (Cohort II). Kaplan-Meier analysis
and Cox proportional hazards modeling were used to estimate the risk of recurrence-free survival (RFS) and the
effect of HMG-CoAR expression on tamoxifen response.
Results: HMG-CoAR protein and RNA expression were decreased in tamoxifen-resistant MCF7-LCC9 cells compared
with their tamoxifen-sensitive parental cell line. HMG-CoAR mRNA expression was decreased in tumors that
recurred following tamoxifen treatment (P < 0.001) and was an independent predictor of RFS in Cohort I (hazard
ratio = 0.63, P = 0.009). In Cohort II, adjuvant tamoxifen increased RFS in HMG-CoAR-positive tumors (P = 0.008).
Multivariate Cox regression analysis demonstrated that HMG-CoAR was an independent predictor of improved RFS
in Cohort II (hazard ratio = 0.67, P = 0.010), and subset analysis revealed that this was maintained in estrogen
receptor (ER)-positive patients (hazard ratio = 0.65, P = 0.029). Multivariate interaction analysis demonstrated a
difference in tamoxifen efficacy relative to HMG-CoAR expression (P = 0.05). Analysis of tamoxifen response
revealed that patients with ER-positive/HMG-CoAR tumors had a significant response to tamoxifen (P = 0.010) as
well as patients with ER-positive or HMG-CoAR-positive tumors (P = 0.035). Stratification according to ER and HMG-
CoAR status demonstrated that ER-positive/HMG-CoAR-positive tumors had an improved RFS compared with ER-
positive/HMG-CoAR-negative tumors in the treatment arm (P = 0.033); this effect was lost in the control arm (P =
0.138), however, suggesting that HMG-CoAR predicts tamoxifen response.
Conclusions: HMG-CoAR expression is a predictor of response to tamoxifen in both ER-positive and ER-negative
disease. Premenopausal patients with tumors that express ER or HMG-CoAR respond to adjuvant tamoxifen.
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Introduction
3-Hydroxy-3-methylglutharyl-coenzyme A reductase
(HMG-CoAR) acts as a rate-limiting enzyme in the
mevalonate pathway. The main product of the mevalo-
nate pathway is cholesterol; however, the pathway also
produces a number of nonsterol isoprenoid side pro-
ducts, which are important regulators of angiogenesis,
proliferation, and migration [1,2]. HMG-CoAR inhibi-
tors (statins) have demonstrated anti-neoplastic effects
in vitro [3-5] and in xenograft models [5]. Statins have
been suggested to lower the cancer incidence [6], but to
date epidemiological studies have failed to confirm an
association between statin use and overall breast cancer
risk [7-10]. A lower incidence of estrogen receptor (ER)-
negative tumors has, however, been reported among sta-
tin users [11]. Furthermore, an inverse relationship
between postdiagnosis statin use and breast cancer
recurrence has been reported [12].
We previously demonstrated an association between
tumor-specific HMG-CoAR expression and improved
prognosis in both breast cancer and epithelial ovarian
cancer [13-15]. Using immunohistochemistry in 511
incident breast cancer cases within the population-based
prospective cohort Malmö Diet and Cancer Study [16],
we demonstrated that increased levels of HMG-CoAR
protein expression were associated with favorable char-
acteristics such as a smaller tumor size, low histological
grade and ER positivity [13]. A validation study con-
firmed these findings and demonstrated that HMG-
CoAR was an independent prognostic marker, asso-
ciated with an improved recurrence-free survival (RFS)
that was particularly evident in ER-positive tumors [14].
Based on these findings we sought to investigate the
predictive value HMG-CoAR expression in tamoxifen-
treated breast cancer patients. The relationship between
HMG-CoAR expression and tamoxifen response was
initially examined in vitro using a cell line model of
tamoxifen resistance [17]. HMG-CoAR mRNA expres-
sion was then examined in a gene expression dataset
published by Chanrion and colleagues containing 155
primary breast tumors obtained from patients treated
with 5 years of adjuvant tamoxifen [18]. Finally HMG-
CoAR protein expression was examined in premenopau-
sal patients with stage II (pT2 N0 M0, pT1-2 N1 M0)
invasive breast cancer. These patients had participated
in a prospective randomized trial for 2 years of adjuvant
tamoxifen versus no systemic treatment [19].
Materials and methods
Cell lines
MCF-7 cells and their tamoxifen-resistant derivative
LCC9 were obtained from Prof. Robert Clarke (George-
town University, Washington, DC, USA) and were
maintained as previously described [17].
Western blotting
Western blot analysis was performed as previously
described [20]. The primary antibody used was a poly-
clonal anti-HMG-CoAR antibody (Upstate catalog num-
ber 07-457; Millipore, Temecula, CA, USA) diluted
1:500 (2 μg/ml). An anti-b-actin antibody (Clone 8226;
Abcam, Cambridge, UK) at a dilution of 1:5000 was
used as a loading control.
Cell pellet arrays
Cell lines were fixed in 4% formalin and processed in
gradient alcohols. Cell pellets were cleared in xylene and
washed multiple times in molten paraffin. Once pro-
cessed, cell lines were arrayed in duplicate 1.0 mm cores
using a manual tissue arrayer (MTA-1; Beecher Instru-
ments Inc., Sun Prairie, WI, USA).
Quantitative SYBR Green real-time PCR
Total RNA was isolated from cell lines using Trizol (Invi-
trogen, Carlsbad, CA, USA) and reverse-transcribed using
SuperScript II™ Reverse Transcriptase (Invitrogen)
according to the manufacturer’s instructions. HMG-CoAR-
F (5’-GGACCCCTTTGCTTAGATGAAA-3’) and HMG-
CoAR-R (5’-CCACCAAGACCTATTGCTCTG-3’) primers
were designed using Primer Express software (Version 2.0;
Applied Biosystems, Warrington, UK) and were used to
amplify a HMG-CoAR-specific DNA fragment with SYBR
Green PCR Master Mix (Applied Biosystems) using a
7900HT Fast Real-Time PCR System (Applied Biosystems).
Relative HMG-CoAR expression levels in untreated MCF-7
cells versus LCC9 cells were calculated using the qBase
real-time PCR relative quantification software [21], with all
samples normalized to 18s rRNA. Negative controls
included a no-template control and a no-reverse-transcrip-
tase control. All quantitative reverse transcriptase PCR
reactions were performed in triplicate.
MTT assay
The tamoxifen response in MCF-7 and LCC9 cells was
measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay. A sample of 105
cells was plated in 96-well plates and grown for 48 hours.
Fresh medium containing various concentrations of 4-
hydroxy-tamoxifen (Sigma, Saint Louis, MO, USA) was
added to each well and cells were incubated for 5 days. On
day 5, 50 μl of 5 mg/ml MTT (Sigma) in PBS were added
to each well. After 4 hours at 37°C, the medium was care-
fully removed from the wells and the remaining formazan
crystals were dissolved in dimethylsulfoxide. The absor-
bance at 570 nm was read on a microplate reader.
Patients
Cohort I consisted of a gene expression dataset published
by Chanrion and colleagues [18], containing 155 primary
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breast tumors obtained from patients who had under-
gone initial surgery between 1989 and 2001 at the Cancer
Research Center of Val d’Aurelle in Montpellier, the Ber-
gonié Institute in Bordeaux, or the Department of Obste-
trics and Gynecology of Turin. The median follow-up
time for all patients was 5.5 years. The aim of this study
was to identify a gene expression signature associated
with tamoxifen resistance. Eight tumors were ER-nega-
tive, and six of these tumors were progesterone receptor
(PR)-positive. No patient received neoadjuvant or adju-
vant systemic chemotherapy as first-line therapy. All
patients were treated with adjuvant tamoxifen (20 mg
daily) for 5 years. One hundred and twenty-one patients
also received adjuvant radiotherapy. Recurrence was
observed in 52 patients (48 distant metastases and four
local recurrences) with a median relapse time of 37.1
months. Raw gene expression data and clinical data were
downloaded from Gene Expression Omnibus [GEO:
GSE9893] [22]. The log ratio of gene expression values
was used without further transformation. For statistical
analysis, HMG-CoAR expression levels were analyzed as
a continuous variable.
Cohort II consisted of 564 premenopausal women with
primary breast cancer in the south and southeast regions
of Sweden were enrolled in a multicenter clinical trial and
were randomized to either 2 years of adjuvant tamoxifen
(n = 276) or a control group (n = 288) irrespective of hor-
monal receptor status [19]. The aim of this study was to
examine the effect of tamoxifen on RFS, and the study has
been described in detail elsewhere [19]. RFS was consid-
ered local, regional, distant recurrences and breast cancer-
specific death, but not contralateral breast cancer. The
inclusion criteria were premenopausal patients, or patients
younger than 50 years, with stage II (pT2 N0 M0, pT1-2
N1 M0) invasive breast cancer treated by modified radical
mastectomy or breast-conserving surgery with axillary
lymph node dissection. Postoperative radiotherapy (50 Gy)
was administered after breast-conserving surgery, and all
lymph-node-positive patients received locoregional radio-
therapy. Less than 2% of the patients received adjuvant
systemic chemotherapy. The median follow-up time for
patients without breast cancer events was 13.9 years. The
ethics committees at Lund and Linköping Universities
approved the study. Oral informed consent was registered
for all patients. The results of the trial have been pre-
viously described [19] and the trial has been included in
the Oxford meta-analysis [23].
Tissue microarray construction
Five hundred paraffin-embedded tumor specimens were
used for tissue microarray (TMA) construction. TMAs
were constructed as described previously [24]. In brief,
two 0.6 mm cores were taken from areas representative
of invasive cancer and were mounted in a recipient
block using a manual arraying device (MTA-1; Beecher
Inc.). The study was approved by the ethics committees
at Linköping University and Lund University.
Immunohistochemistry
Four-micometer sections from the TMAs and 3.5 μm
sections from the cell pellet arrays were automatically
pretreated using the PT-link system (DAKO, Copenha-
gen, Denmark) and were then stained in a Techmate
500 (DAKO) with a polyclonal anti-HMG-CoAR anti-
body (Upstate catalog number 07-457) diluted 1:250.
For all other antibodies, heat-mediated antigen retrieval
was performed using microwave treatment for 2 × 5 min-
utes in a citrate buffer before being processed either in
the Ventana Benchmark system (Ventana Medical Sys-
tems Inc., Tucson, AZ, USA) using pre-diluted antibodies
to ER (anti-ER, clone 6F11), PR (anti-PgR, clone 16) and
Her2 (Pathway CB-USA, 760-2694) or in the Techmate
500 (DAKO) for Ki-67 (1:200, M7240; DAKO).
Cytoplasmic staining of HMG-CoAR was assessed by
two investigators, one of whom is a board-certified
pathologist (KJ), according to intensity (negative = 0,
weak = 1, moderate = 2, strong = 3). HMG-CoAR was
not expressed in the nucleus. Discordant cores were
reassessed jointly and a consensus was reached. HER2
and Ki-67 were assessed as previously described [20].
ER-negativity and PR-negativity was defined as <10%
positively staining nuclei, according to current clinical
guidelines in Sweden.
Statistical analysis
Differences in distribution of clinical data and tumor
characteristics between HMG-CoAR-negative and HMG-
CoAR-positive tumors were evaluated using the chi-
square test. Kaplan-Meier analysis and the log-rank test
were used to illustrate differences between RFS according
to HMG-CoAR expression. Cox regression proportional
hazards models were used to estimate the impact of
HMG-CoAR expression on RFS and overall survival (OS)
in both univariate and multivariate analysis, adjusted for
tumor size, age at diagnosis, ER status, HER2 status,
lymph node status and Nottingham Histological Grade in
the entire cohort. Cox proportional hazards models were
used to estimate relative hazards adjusted or not for
potential prognostic factors. The model was used in
Cohort II to estimate the interaction effect between
tamoxifen treatment and HMG-CoAR expression in
order to measure any possible difference in treatment
effect based on HMG-CoAR expression. For this purpose
an interaction variable was constructed: TAM treatment
(+/-) × HMG-COAR (+/-). All calculations were per-
formed using SPSS version 15.0 (SPSS Inc., Chicago, IL,
USA). All statistical tests were two-sided and P < 0.05
was considered statistically significant.
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Results
HMG-CoAR is associated with tamoxifen response in vitro
The specificity of the anti HMG-CoAR antibody was
confirmed in a previous study [13]. The anti-HMG-
CoAR antibody recognized a single distinct band at ~90
kDa in MCF7 cells. HMG-CoAR protein expression was
significantly decreased in the tamoxifen-resistant deriva-
tive LCC9 cell line (Figure 1a). HMG-CoAR mRNA
expression was also decreased in the LCC9 cells com-
pared with their MCF7 derivatives (Figure 1b). Immuno-
histochemistry performed on the same cell lines
confirmed these results (Figure 1c). Finally treatment of
Figure 1 HMG-CoAR expression is associated with tamoxifen response in vitro. (a) Western blot demonstrating increased expression of 3-
hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) in tamoxifen-sensitive MCF7 cells compared with their tamoxifen-resistant
derivatives LCC9. (b) Quantitative reverse transcriptase PCR demonstrating increased expression of HMG-CoAR mRNA in MCF7 cells compared
with LCC9 cells. (c) Immunohistochemistry demonstrating increased HMG-CoAR protein expression in MCF7 cells compared with LCC9 cells. (d)
MTT assay demonstrating improved tamoxifen response in MCF7 cells compared with LCC9 cells.
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the cell lines with tamoxifen demonstrated anti-estrogen
resistance in the LCC9 cells compared with their MCF7
derivatives (Figure 1d).
HMG-CoAR mRNA expression is associated with a
prolonged recurrence-free survival in tamoxifen-treated
breast cancer patients
The relationship between HMG-CoAR mRNA expression
and tamoxifen response was examined in Cohort I. Chan-
rion and colleagues’ dataset consists of patients treated
with 5 years of adjuvant tamoxifen and contains both pre-
menopausal and postmenopausal patients [18]. HMG-
CoAR mRNA levels were higher in patients who remained
disease-free following tamoxifen treatment compared with
those who developed recurrences (Figure 2a). Using a
threshold of mean expression, Kaplan-Meier analysis
demonstrated that increased HMG-CoAR mRNA expres-
sion was associated with a prolonged RFS (P = 0.018)
(Figure 2b).
Examination of the relationship between HMG-CoAR
mRNA expression and other clinicopathological para-
meters revealed that increased HMG-CoAR mRNA
expression was associated with small (P = 0.003), lymph-
node-negative (P = 0.003) tumors (Table 1). Univariate
analysis of HMG-CoAR as a continuous variable revealed
that increased levels of HMG-CoAR mRNA were asso-
ciated with a prolonged RFS and OS in Cohort I (Table 2).
Multivariate Cox regression analysis controlling for grade,
age, nodal status and tumor size confirmed that HMG-
CoAR was an independent predictor of RFS (hazard
ratio = 0.63, 95% confidence interval = 0.45 to 0.89,
P = 0.009) and OS (hazard ratio = 0.49, 95% confidence
interval = 0.32 to 0.75, P = 0.001) (Table 2), suggesting
that HMG-CoAR may play an important role in tamoxi-
fen-treated breast cancer patients.
HMG-CoAR protein expression predicts tamoxifen
response in premenopausal breast cancer
Having demonstrated a relationship between HMG-CoAR
mRNA expression in tamoxifen-treated patients, we pro-
ceeded to examine HMG-CoAR protein expression in
Cohort II. Tumor samples were available from 500 of 564
patients (89%) included in the randomized study. Follow-
ing antibody optimization and staining, it was possible to
evaluate the expression of HMG-CoAR protein in 422
(84.4%) of the 500 tumors represented on the TMA.
Only staining intensity was accounted for in the statis-
tical analyses of HMG-CoAR protein expression, as
HMG-CoAR, when present, was generally expressed in
the majority of tumor cells (>50%) - a finding consistent
with previous studies [13,14]. Two hundred and twenty-
three (52.7%) tumors lacked HMG-CoAR expression,
163 (38.5%) demonstrated a weak signal, 37 (8.7%) a
moderate signal and none demonstrated a strong signal.
Examples of HMG-CoAR expression are illustrated in
Figure 3a.
To validate our previous findings [13,14], and also to
identify any differences in HMG-CoAR expression in an
exclusively premenopausal cohort, the relationship
between HMG-CoAR protein expression and established
clinicopathological variables was evaluated. As demon-
strated in Table 1, HMG-CoAR expression, dichotomized
to absent staining versus any staining, was associated with
low histological grade (P = 0.009), ER-positivity (P =
0.026), and Her2 overexpression (P = 0.008). HMG-CoAR
Figure 2 HMG-CoAR mRNA expression is associated with
increased recurrence-free survival in tamoxifen-treated breast
cancer patients. (a) Mean 3-hydroxy-3-methylglutharyl-coenzyme A
reductase (HMG-CoAR) mRNA levels were significantly higher in
patients who remained disease-free after tamoxifen treatment. *P <
0.001. (b) Kaplan-Meier using estimates of recurrence-free survival
according to HMG-CoAR mRNA expression using mean HMG-CoAR
expression as a threshold.
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protein expression was associated with lymph-node-posi-
tivity in Cohort II (P = 0.009).
Assessment of the evaluable tumors in Cohort II (n =
422) revealed that HMG-CoAR protein expression was
associated with a stepwise increased RFS (P = 0.028)
when analyzed in three groups (negative, 1+ and 2+)
(Figure 3b). Dichotomization of HMG-CoAR protein
expression data to absent expression versus any expres-
sion demonstrated an association with an improved RFS
(P = 0.008) (Figure 3c). HMG-CoAR was also associated
with an improved breast-cancer-specific survival and OS
(data not shown). As the aim of the original trial was to
examine the effect of tamoxifen on RFS, this was used
as the endpoint in this study. As illustrated in Table 3,
multivariate Cox regression analysis revealed that HMG-
CoAR expression was an independent positive prognos-
tic factor in the evaluated cohort (hazard ratio = 0.67,
95% confidence interval = 0.49 to 0.91, P = 0.010).
The aim of the present study was to evaluate the poten-
tial role of HMG-CoAR expression in predicting response
Table 1 Clinical and tumor characteristics stratified according to HMG-CoAR protein expression in two independent
cohorts
Cohort I Cohort II
Low HMG-CoAR }
(%) (n = 62)
High HMG-CoAR
(%) (n = 93)
P value
(c2 test)
HMG-CoAR-negative
(%) (n = 222)
HMG-CoAR-positive
(%) (n = 200)
P value
(c2 test)
Age (years)
<median 34 (55) 42 (45) 0.238 36 (16) 36 (18) 0.612
>median 28 (45) 51 (55) 186 (84) 164 (82)
Tumor size
0 to 20 mm 21 (35) 57 (63) 0.003 75 (34) 79 (40) 0.196
>21 mm 39 (65) 33 (37) 147 (66) 120 (60)
Missing 5
Histological subtype
Ductal 49 (79) 75 (81) 0.250 181 (91) 171 (93) 0.581
Others 13 (21) 18 (19) 17 (9) 13 (7)
Unknown 40
Nodal status
N0 21 (35) 57 (63) 0.003 70 (32) 42 (21) 0.009
N1+ 39 (65) 33 (37) 152 (68) 158 (79)
Unknown 5
Nottingham Histological Grade
I 9 (15) 12 (13) 0.535 15 (7) 28 (15) 0.009
II 38 (60) 56 (60) 85 (40) 86 (45)
III 10 (14) 23 (27) 115 (53) 79 (40)
Unknown 7 14
ER status
Negative 80 (38) 54 (28) 0.026
Positive 130 (62) 141 (72)
Unknown 17
PR status
Negative 78 (38) 56 (30) 0.098
Positive 130 (62) 133 (70)
Unknown 25
Ki-67
<10% 138 (73) 128 (71) 0.658
>10% 52 (27) 53 (29)
Unknown 51
Her2 immunohistochemistry
0 to 2+ 173 (90) 137 (80) 0.008
3+ 20 (10) 35 (20)
Unknown 57
Data in parenthesis are percentages unless otherwise stated. ER, estrogen receptor; HMG-CoAR, 3-hydroxy-3-methylglutharyl-coenzyme A reductase; N0, node-
negative; N1+, node-positive; PR, progesterone receptor.
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Table 2 Cox analysis of recurrence-free and overall survival according to HMG-CoAR mRNA expression in Cohort I
Recurrence-free survival Overall survival
Univariate Multivariatea Univariate Multivariatea
HR 95% CI P
value
HR 95% CI P
value
HR 95% CI P
value
HR 95% CI P
value
HMG-CoAR mRNA (continuous) 0.64 0.48 to
0.85
0.002 0.63 0.45 to
0.89
0.009 0.55 0.41 to
0.75
<0.001 0.49 0.32 to
0.75
0.001
Size (continuous) 1.02 0.99 to
1.05
0.175 1.02 0.97 to
1.07
0.439 0.99 0.96 to
1.04
0.89 0.98 0.93 to
1.04
0.581
Grade (I and II vs. III) 2.62 1.62 to
4.23
<0.001 3.13 1.80 to
5.44
<0.001 2.95 1.70 to
5.14
<0.001 4.32 2.22 to
8.41
<0.001
Nodal status (negative vs.
positive)
2.80 1.44 to
5.42
0.002 1.13 1.10 to
1.21
<0.001 5.49 2.29-13.17 <0.001 1.12 1.04 to
1.20
0.004
Age (continuous) 1.02 0.99 to
1.04
0.23 0.99 0.96 to
1.03
0.700 1.01 0.98 to
1.04
0.599 0.99 0.95 to
1.03
0.566
CI, confidence interval; HMG-CoAR, 3-hydroxy-3-methylglutharyl-coenzyme A reductase; HR, hazard ratio. aAdjusted for all other variables in the table.
Figure 3 HMG-CoAR protein expression in Cohort II. (a) Immunohistochemical analysis of 3-hydroxy-3-methylglutharyl-coenzyme A reductase
(HMG-CoAR) demonstrating different levels of staining intensity. (b) Kaplan-Meier estimates of recurrence-free survival according to HMG-CoAR
expression in three groups. (c) Kaplan-Meier estimates of recurrence-free survival according to HMG-CoAR expression (negative = 0 or positive =
1 to 3) in all patients (n = 422).
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to tamoxifen; subset analysis of RFS was therefore per-
formed comparing the effect of tamoxifen versus no treat-
ment based on HMG-CoAR expression. Figure 4a,b
demonstrate that HMG-CoAR expression was associated
with an improved response to tamoxifen in the entire
cohort irrespective of ER status. Cox interaction analysis
confirmed that HMG-CoAR expression was associated
with an improved response to tamoxifen (hazard ratio =
0.5, P = 0.003) in the entire cohort irrespective of ER status.
Stratification according to ER and treatment status
demonstrated that HMG-CoAR expression was asso-
ciated with an improved RFS in all ER-positive patients,
irrespective of treatment status (Figure 4c); this was
confirmed by mutltivariate Cox regression analysis
whereby HMG-CoAR expression was an independent
positive prognostic factor in ER-positive patients (hazard
ratio = 0.65, 95% confidence interval = 0.45 to 0.96, P =
0.029) (Table 3). This effect was maintained when
tamoxifen-treated ER-positive patients were examined
separately (Figure 4d). HMG-CoAR expression was not
associated with a prolonged RFS in untreated ER-posi-
tive patients (Figure 4e), however, suggesting that the
HMG-CoAR status may predict the tamoxifen response.
Based on these findings, the relationship between ER
and HMG-CoAR expression and tamoxifen response was
examined. Three subsets were constructed: ER-negative
and HMG-CoAR-negative (n = 80), ER-positive and
HMG-CoAR-positive (n = 141), and ER-positive or HMG-
CoAR-positive (n = 236). Analysis of these groups revealed
that patients with ER-positive and HMG-CoAR-positive
tumors had a significant response to tamoxifen (P = 0.010)
(Figure 5a) as well as patients with ER-positive or HMG-
CoAR-positive tumors (P = 0.035) (Figure 5b). Double-
negative tumors did not respond to tamoxifen (Figure 5c).
Stratification according to ER and HMG-CoAR status
demonstrated that ER-positive/HMG-CoAR-positive
tumors had an improved RFS compared with ER-positive/
HMG-CoAR-negative tumors in the treatment arm (P =
0.033); this effect was lost in the control arm (P = 0.138),
however, suggesting that HMG-CoAR predicts tamoxifen
response (Figure 5d,e).
Discussion
The aim of the present study was to evaluate HMG-
CoAR expression as a predictive marker of tamoxifen
response. Our results demonstrate a potentially impor-
tant association with tamoxifen response both in vitro
and using two independent breast cancer cohorts, one
of which encompasses a randomized control trial of pre-
menopausal stage II disease.
A wealth of evidence supports the role of tamoxifen in
the treatment of breast cancer [25]; however, resistance to
tamoxifen is a significant clinical problem - and the
Oxford meta-analysis reported a relapse rate of 15%, and
an 8% incidence of breast-cancer-specific mortality within
5 years of the commencement of therapy [25]. The intro-
duction of aromatase inhibitors may lead to an improve-
ment in postmenopausal women [26,27], but resistance to
aromatase inhibitors may become a problem over time. In
premenopausal women, tamoxifen remains the endocrine
drug of choice and both inherent and acquired resistance
may be more prevalent in this population. Tamoxifen
resistance in premenopausal women is quite hard to quan-
tify accurately as the majority of premenopausal patients
receive adjuvant cytotoxic chemotherapy; however, Ryden
and colleagues reported a recurrence rate of 39.7% at 10
years in the absence of adjuvant chemotherapy in the trial
from which Cohort II was derived [19]. An ability to iden-
tify patients who will respond to endocrine therapy prior
to commencing treatment would be extremely beneficial.
Table 3 Cox analysis of recurrence-free survival according to HMG-CoAR protein expression in Cohort II
All tumors (n = 422) ER-positive (n = 270)
Univariate Multivariatea Univariate Multivariatea
HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value
HMG-CoAR (0 vs. 1 to 2+) 0.68 0.51 to 0.90 0.009 0.67 0.49 to 0.91 0.01 0.66 0.46 to 0.95 0.024 0.65 0.45 to 0.96 0.029
Grade (I and II vs. III) 1.88 1.46 to 2.42 <0.001 1.58 1.11 to 2.25 0.012 1.85 1.32 to 2.60 <0.001 1.56 1.04 to 2.34 0.03
Age (continuous) 0.95 0.95 to 0.99 0.002 0.97 0.95 to 1.01 0.071 0.95 0.93 to 0.98 0.001 0.95 0.92 to 0.99 0.015
Nodal status
(negative vs. positive)
1.7 1.26 to 2.29 0.001 2.12 1.47 to 3.28 <0.001 1.42 0.94 to 2.15 0.098 1.56 0.95 to 2.57 0.079
Tumor size (continuous) 1.16 0.90 to 1.50 0.254 1.27 0.91 to 1.77 0.159 1.17 0.84 to 1.64 0.361 1.22 0.81 to 1.84 0.352
ER status (0 to 10%
vs. 11 to 100%)
0.71 0.54 to 0.94 0.018 0.65 0.37 to 1.13 0.126
PR status (0 to 10%
vs. 11 to 100%)
0.73 0.54 to 0.97 0.031 1.37 0.77 to 2.43 0.285 0.94 0.832 to 1.19 0.95 2.28 0.72 to 7.27 0.163
Treatment (tamoxifen
vs. control)
0.78 0.60 to 0.98 0.033 0.68 0.50 to 0.92 0.011 0.61 0.44 to 0.86 0.005 0.58 0.39 to 0.84 0.005
CI, confidence interval; ER, estrogen receptor; HMG-CoAR, 3-hydroxy-3-methylglutharyl-coenzyme A reductase; HR, hazard ratio; PR, progesterone receptor.
aAdjusted for all other variables in the table.
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Figure 4 HMG-CoAR protein expression is associated with tamoxifen response in Cohort II. (a) Kaplan-Meier estimate of recurrence-free
survival comparing 2 years of tamoxifen treatment with no adjuvant treatment in 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-
CoAR)-negative tumors. (b) Kaplan-Meier estimate of recurrence-free survival comparing 2 years of tamoxifen treatment with no adjuvant
treatment in HMG-CoAR-positive tumors. (c) Kaplan-Meier estimate of recurrence-free survival in all estrogen receptor (ER)-positive tumors. (d)
Kaplan-Meier estimate of recurrence-free survival in tamoxifen-treated ER-positive tumors. (e) Kaplan-Meier estimate of recurrence-free survival in
untreated ER-positive tumors. HR, hazard ratio.
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Figure 5 Relationship between estrogen receptor, HMG-CoAR and tamoxifen response in premenopausal breast cancer. (a) Kaplan-
Meier estimate of recurrence-free survival based on tamoxifen treatment in estrogen receptor (ER)-positive and 3-hydroxy-3-methylglutharyl-
coenzyme A reductase (HMG-CoAR)-positive tumors (n = 141). (b) Kaplan-Meier estimate of recurrence-free survival based on tamoxifen
treatment in ER-positive or HMG-CoAR-positive tumors (n = 236). (c) Kaplan-Meier estimate of recurrence-free survival based on tamoxifen
treatment in ER-negative and HMG-CoAR-negative tumors (n = 80). (d) Kaplan-Meier estimate of recurrence-free survival in tamoxifen-treated ER-
positive patients based on HMG-CoAR expression. (e) Kaplan-Meier estimate of recurrence-free survival in untreated ER-positive patients based
on HMG-CoAR expression. HR, hazard ratio.
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To that end, the data presented here are particularly
interesting. Cox regression analysis confirmed HMG-
CoAR was an independent prognostic marker in both
cohorts. Cohort I was a nonrandomized cohort consist-
ing of a mixture of premenopausal and postmenopausal
patients and therefore cannot be used to validate a pre-
dictive biomarker; however, this cohort provides impor-
tant information, particularly as HMG-CoAR mRNA
expression was measured as a continuous variable. The
relationship between HMG-CoAR protein expression
and tamoxifen response was examined in Cohort II, a
randomized exclusively premenopausal cohort, and a
Cox interaction analysis revealed an interaction between
tamoxifen treatment and HMG-CoAR expression. Sub-
set analysis of Cohort II revealed that tumors expressing
both ER and HMG-CoAR were particularly sensitive to
tamoxifen, but tumors that expressed either ER or
HMG-CoAR also responded to tamoxifen. In addition
HMG-CoAR-positive/ER-positive patients had a signifi-
cantly improved response to tamoxifen compared with
HMG-CoAR-negative/ER-positive patients.
In contrast to previous studies by our group, none of
the tumors expressed high levels (3+) of HMG-CoAR.
This difference could potentially be explained by the fact
that Cohort II was an exclusively premenopausal cohort
with stage II breast cancer, which also explains the posi-
tive association with lymph node status seen in the pre-
sent study. In our two previous breast cancer studies we
demonstrated an inverse relationship between tumor size
and HMG-CoAR [13,14], and therefore the absence of
small stage I tumors from Cohort II could explain the
lack of tumors expressing high levels of HMG-CoAR in
this study. This argument is further strengthened by the
inverse relationship between HMG-CoAR mRNA expres-
sion and tumor size demonstrated in Cohort I in this
study, as this cohort also included a significant number
of small stage I tumors. We are unable to explain the
positive association between Her2 and HMG-CoAR seen
in Cohort II, but this could potentially be explained by
the association with lymph-node-positivity.
Such findings raise the possibility of pharmacological
interventions to increase tumor-specific HMG-CoAR
expression as a potential therapeutic option for breast can-
cer. Statin-induced mevalonate depletion has been shown
to result in an adaptive induction of HMG-CoAR expres-
sion in Chinese hamster ovary cells [28] and MCF7 breast
cancer cells [29]. Treatment of MCF7 cells with mevasta-
tin resulted in a 10-fold to 15-fold induction of HMG-
CoAR activity in association with a 2.5-fold to 3.5-fold
induction of HMG-CoA reductase mRNA expression [29],
suggesting that treatment with statins may increase
tumor-specific HMG-CoAR expression in vivo; however,
this suggestion remains to be fully elucidated. Given our
findings that increased levels of HMG-CoAR expression
are associated with an improved response to tamoxifen in
ER-positive tumors, a combination of tamoxifen and sta-
tins may be a new therapeutic option. Further studies,
however, are required to investigate the value of HMG-
CoAR expression as a predictive marker of response to
statin treatment.
Despite an ever-growing body of literature describing
the anti-neoplastic properties of statins, epidemiologic
data regarding their preventive effect against cancer in
general - and breast cancer in particular - remain incon-
clusive [7,9,30-32]. In the adjuvant setting, a recent pre-
operative window trial of ductal carcinoma in situ and
stage I breast cancer was the first to demonstrate that
statins can inhibit proliferation and increase apoptosis
in vivo [33], raising the possibility that the combination
of statins and well-established chemotherapeutic and
endocrine agents may be an option. A synergism
between statins and trastuzumab, rapamycin and epiru-
bicin has been demonstrated in breast cancer cell lines
[34]; however, a synergistic relationship between tamoxi-
fen and statins has yet to be investigated.
Conclusions
These data describe HMG-CoAR as a significant predictor
of tamoxifen response in premenopausal breast cancer
patients with both ER-positive and ER-negative tumors.
Using a cohort of patients who had participated in a ran-
domized control trial with long-term follow-up, we have
demonstrated that tumor-specific HMG-CoAR expression
predicts response to tamoxifen. Tumors that express both
ER and HMG-CoAR had an excellent response to tamoxi-
fen, but tumors that express ER or HMG-CoAR also
respond to tamoxifen. These findings suggest that the
combination of tamoxifen and statins may be a viable and
well-tolerated therapeutic option for a subset of breast
cancer patients, which warrants further investigation.
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